NASDAQ:EPRX Eupraxia Pharmaceuticals (EPRX) Stock Price, News & Analysis $7.59 +0.64 (+9.21%) Closing price 04:00 PM EasternExtended Trading$7.62 +0.03 (+0.33%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Eupraxia Pharmaceuticals Stock (NASDAQ:EPRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get EPRX alerts:Sign Up Key Stats Today's Range$6.87▼$7.7650-Day Range$6.34▼$9.1052-Week Range$5.25▼$9.32Volume938,286 shsAverage Volume374,891 shsMarket Capitalization$493.50 millionP/E RatioN/ADividend YieldN/APrice Target$17.80Consensus RatingModerate Buy Company Overview Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions. Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee. The company’s approach is intended to provide sustained drug delivery within the affected joint and is based on its proprietary DiffuSphere technology. The company has also developed EP-7041, an investigational small-molecule inhibitor of factor XIa being evaluated for its potential use in preventing and treating blood clots. Eupraxia does not currently have marketed products and remains focused on research, clinical development and potential commercialization through regulatory approval and strategic partnerships.AI Generated. May Contain Errors. Read More Eupraxia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks60th Percentile Overall ScoreEPRX MarketRank™: 2.992841044675 of 5 starsEupraxia Pharmaceuticals scored higher than 60% of companies evaluated by MarketBeat, and ranked 371st out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingEupraxia Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEupraxia Pharmaceuticals has a consensus price target of $17.80, representing about 130.1% upside from its current price of $7.74.Amount of Analyst CoverageEupraxia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Eupraxia Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Eupraxia Pharmaceuticals are expected to decrease in the coming year, from ($0.85) to ($0.99) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eupraxia Pharmaceuticals is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eupraxia Pharmaceuticals is -7.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEupraxia Pharmaceuticals has a P/B Ratio of 5.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Eupraxia Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.46% of the float of Eupraxia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEupraxia Pharmaceuticals has a short interest ratio ("days to cover") of 11.07, which indicates bearish sentiment.Change versus previous monthShort interest in Eupraxia Pharmaceuticals has recently decreased by 10.33%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEupraxia Pharmaceuticals does not currently pay a dividend.Dividend GrowthEupraxia Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.29 News SentimentEupraxia Pharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Eupraxia Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest2 people have searched for EPRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eupraxia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InstitutionsEupraxia Pharmaceuticals has minimal institutional ownership at this time.Read more about Eupraxia Pharmaceuticals' insider trading history. Receive EPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EPRX Stock News HeadlinesEupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Lowered by Wall Street ZenOctober 19 at 1:55 AM | americanbankingnews.comEupraxia Pharmaceuticals (EPRX) Receives a Buy from WedbushOctober 17 at 11:20 PM | theglobeandmail.comI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any regular brokerage account gives investors exposure to SpaceX and 66 of its neighbors, without an IPO allocation. He is also naming two space stocks he would consider dumping before December, plus a $14 stock that Elon has personally put his name on.October 20 at 1:00 AM | Behind the Markets (Ad)Eupraxia Pharmaceuticals Inc. Reaches Enrollment Target For RESOLVE Trial Investigating EP-104GI For Treatment Of Eosinophilic EsophagitisOctober 15, 2026 | marketscreener.comMEupraxia Pharmaceuticals Says Phase 2b Trial in Eosinophilic Esophagitis Meets Enrollment TargetOctober 15, 2026 | marketscreener.comMEupraxia Pharmaceuticals Reaches its Enrollment Target for the RESOLVE Trial Investigating EP-104GI for the Treatment of Eosinophilic EsophagitisOctober 15, 2026 | globenewswire.comEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesOctober 9, 2026 | financialpost.comFEupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical ConferencesOctober 9, 2026 | globenewswire.comSee More Headlines EPRX Stock Analysis - Frequently Asked Questions How have EPRX shares performed this year? Eupraxia Pharmaceuticals' stock was trading at $7.55 at the start of the year. Since then, EPRX stock has increased by 2.5% and is now trading at $7.7370. How were Eupraxia Pharmaceuticals' earnings last quarter? Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) issued its earnings results on Tuesday, August, 11th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. How do I buy shares of Eupraxia Pharmaceuticals? Shares of EPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today10/20/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (5d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 5 days ago, EPRX's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:EPRX Previous SymbolNASDAQ:EPRX CIK1581178 Webwww.eupraxiapharma.com Phone250-590-3968FaxN/AEmployees49Year Founded2012Price Target and Rating Average Price Target for Eupraxia Pharmaceuticals$17.80 High Price Target$25.00 Low Price Target$11.00 Potential Upside/Downside+134.5%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$38.58 million Net MarginsN/A Pretax MarginN/A Return on Equity-63.97% Return on Assets-43.32% Debt Debt-to-Equity Ratio0.02 Current Ratio16.00 Quick Ratio16.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book5.38Miscellaneous Outstanding Shares65,020,000Free FloatN/AMarket Cap$493.50 million OptionableN/A Beta0.83 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:EPRX) was last updated on 10/20/2026 by MarketBeat.com Staff. From Our PartnersTrump’s Plan To Cheat HistoryChina has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and ...Porter & Company | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredLast call for your free 0DTE reportThe 0DTE Game Plan lays out a simple 3-step framework for trading same-day options: Plan it, profit from it, p...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredDon't lose access to thisIan Cooper's guide, 'The $50-to-$500 Options Strategy,' is still available for free download, but not for long...TradeWins | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredThe Iran War Isn’t Chaos. It’s Strategy.Two thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredPalantir and Wall Street are in on it…Palantir just signed a major AI deal with a company most investors have never heard of. Wall Street has pou...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
